High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy

Haematologica

Volumn 93, Issue 3, 2008, Pages 475-476

  Dungarwalla, Moez ^a   Evans, Steve O ^a   Riley, Unell ^a   Catovsky, Daniel ^a   Dearden, Clare E ^a   Matutes, Estella ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; ANTIBIOTIC AGENT; CHLORAMBUCIL; CISPLATIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DAUNORUBICIN; EPIRUBICIN; FLUCONAZOLE; FLUDARABINE; MELPHALAN; METHYLPREDNISOLONE; MITOXANTRONE; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CAUSE OF DEATH; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE DURATION; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYCOSIS; PNEUMONIA; PROGNOSIS; SEPTICEMIA; SPLENECTOMY; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS INFECTION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOTHERAPY; INFECTION; INFECTION CONTROL; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; METHYLPREDNISOLONE; MIDDLE AGED; SALVAGE THERAPY; VIDARABINE;

EID: 40849094878     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.11903     Document Type: Article

References (10)

1. Thornton PD, Matutes E, Bosanquet AG, Lakhani AK, Grech H, Ropner JE, et al. High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities. Ann Hematol 2003;82:759-65.
2. Thornton PD, Hamblin M, Treleaven JG, Matutes E, Lakhani AK, Catovsky D. High dose methylprednisolone in refractory chronic lymphocytic leukaemia. Leuk Lymphoma 1999;4:167-70.
3. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, et al. National Cancer Institute sponsored Working Group guidelines for chronic lymphocytic leukaemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990-7.
4. Molica S. Infections in chronic lymphocytic leukaemia: risk factors and impact on survival and treatment. Leuk Lymphoma 1994;13:203-14.
5. Glasmacher A, Prentice A, Gorschlüter M, Engelhart S, Hahn C, Djulbegovic B, et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for haematological malignancies: evidence from a meta-analysis of 3,597 patients. J Clin Oncol 2003;21:4615-26.
6. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, et al. Posaconazole vs Fluconazole or Itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348-59.
7. McConkey DJ, Chandra J. Protease activation and glucocorticoid induced apoptosis in chronic lymphocytic leukaemia. Leuk Lymphoma 1999;33:421-31.
8. Mori N, Yamate J, Stassen AP, Oka S, Okumoto M, Tsubura A, et al. Modulations of glucocorticoid-induced apoptosis linked to the p53 deletion and to the apoptosis susceptibility gene Rapop1 (Radiation induced apoptosis 1). Oncogene 1999;18:4282-5.
9. Smets LA, Salomons G, Van den Berg J. Glucocorticoid induced apoptosis in leukaemia. Adv Exp Med Biol 1999;457:607-14.
10. Riccardi C. Glucocorticoid hormones in the regulation of cell death. Pharmacol Exp 2000;55:165-9.